Mirena IUD and Breast Cancer Risk

Absolute Risk Increase

• Baseline breast cancer incidence in reproductive-age women (20-49 years) is approximately 72 per 100,000 women annually, according to the Centers for Disease Control and Prevention (CDC) 1
• The breast cancer risk associated with combined oral contraceptives is higher, with current users showing a relative risk of 1.24, as reported by the American College of Obstetricians and Gynecologists (ACOG) 2

Clinical Guideline Framework

• The U.S. Medical Eligibility Criteria, as stated by the Centers for Disease Control and Prevention (CDC), classifies breast cancer scenarios for LNG-IUD use, including current breast cancer as Category 4 (unacceptable health risk) - do not initiate 3
• The U.S. Medical Eligibility Criteria also categorizes past breast cancer with no evidence of disease for 5 years as Category 3, indicating theoretical risks usually outweigh advantages, as recommended by the CDC 3
• The American College of Obstetricians and Gynecologists (ACOG) notes that family history of breast cancer is categorized as Category 1, with no restriction, though this predates the 2024 interaction data 3